UK-US pharma deal could lead to nearly 230,000 unnecessary deaths in England, analysis says
UK-US Pharma Deal Could Cause 230,000 Extra Deaths in England, Study Finds
UK US pharma deal could lead – A new study warns that the UK-US pharmaceutical trade agreement may result in an estimated 230,000 additional deaths in England by 2036. The analysis, published in *The British Medical Journal*, highlights how increased spending on imported medicines could divert critical funding from other essential healthcare services, threatening the sustainability of the National Health Service (NHS). Researchers from the University of York, University of Liverpool, and Christchurch Hospital in New Zealand argue that this reallocation of resources risks exacerbating health disparities and undermining the NHS’s ability to deliver timely care to vulnerable populations.
Trade Agreement’s Financial Impact
The UK-US pharma deal, finalized in late 2025, mandates a 200% increase in the country’s pharmaceutical spending from 0.3% of GDP to 0.6% over the next decade. This shift, intended to secure access to advanced treatments and reduce tariffs on US imports, comes with a projected £45 billion cost to the NHS by 2036. The analysis suggests this financial burden may not be offset by the US’s promise to exempt British pharmaceuticals from levies, potentially straining budgets already stretched thin by rising healthcare demands.
Experts emphasize that while the agreement aims to boost economic ties, its long-term consequences could be severe. Without additional government funding, the reallocation of resources may force hospitals and clinics to cut back on preventative care, mental health services, and emergency departments. This could lead to delays in treatment and a higher risk of preventable illnesses, contributing to the estimated 230,000 extra deaths in England by 2036.
Health Inequalities and Systemic Concerns
The study identifies specific health conditions most at risk from the deal’s financial impact, including heart disease, respiratory illnesses, and cancer. These areas rely heavily on NHS funding for treatments and ongoing care, and the shift toward pharmaceutical expenditures could leave them under-resourced. The UK-US pharma deal could also widen the gap between wealthier and poorer regions, as areas with limited budgets may struggle to maintain comprehensive healthcare services.
“The UK-US pharma deal could create a scenario where the cost of new medicines overshadows the needs of other critical health programs,” the researchers state. “This could lead to a shortfall in funding for services that prevent diseases and support long-term patient outcomes.”
The analysis further argues that much of the additional spending is likely to benefit multinational pharmaceutical companies rather than directly improving patient care within the UK.
Debating the Economic Rationale
Supporters of the UK-US pharma deal highlight its potential to strengthen economic partnerships and ensure affordable access to life-saving drugs. A Department of Health and Social Care spokesperson noted that the financial burden would be mitigated by the US’s tariff exemption, which they claim could enhance trade and investment. However, the study challenges this perspective, noting that the UK remains a net importer of medicines, meaning the deal’s economic gains may not fully compensate for its healthcare costs.
The researchers warn that the UK-US pharma deal could lock the NHS into a cycle of dependency on foreign pharmaceutical suppliers, limiting opportunities for domestic innovation and self-sufficiency. This concern is amplified by the projected cost increases, which may outpace the value of the US’s tariff concessions, leaving the healthcare system more vulnerable to financial shocks in the future.
Policy Challenges and Future Implications
As the UK-US pharma deal could reshape healthcare priorities, policymakers face a critical decision: how to balance economic benefits with the need to protect essential health services. The analysis underscores that without proactive measures to secure additional funding, the NHS may struggle to meet rising demands while adhering to the deal’s financial commitments. This dilemma reflects a broader challenge in aligning trade agreements with public health goals.
The debate over the UK-US pharma deal could serve as a case study for how global trade policies intersect with domestic healthcare priorities. By prioritizing pharmaceutical imports, the agreement may inadvertently shift focus away from preventative care and community health initiatives, which are vital for reducing long-term disease burdens. The UK-US pharma deal could therefore have far-reaching implications beyond immediate cost increases, influencing the future of healthcare delivery and equity in England.